Notes
2015 US dollars
Reference
Prabhu VS, et al. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection. Clinical Infectious Diseases : 2 Nov 2017. Available from: URL: http://doi.org/10.1093/cid/cix809
Rights and permissions
About this article
Cite this article
Bezlotoxumab cost effective for Clostridium difficile infection. PharmacoEcon Outcomes News 792, 6 (2017). https://doi.org/10.1007/s40274-017-4529-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4529-z